Company news

Tenax Therapeutics, Inc. news in 2024

Tenax Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

November 12, 2024

Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

August 12, 2024

Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program

August 11, 2024

Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement

August 5, 2024

Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 13, 2024

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

April 29, 2024

Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results

March 27, 2024

Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024

February 28, 2024

Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan

February 19, 2024

Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering

February 7, 2024

Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

February 6, 2024

Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

February 5, 2024

Decks in 2024